UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON,	D.C. 20549
WASHING LOIN	D.C. 40377

	FORM 8-A	_
PUF	ATION OF CERTAIN CLASSES O RSUANT TO SECTION 12(b) OR (g SECURITIES EXCHANGE ACT O	OF
	acture Therapeutics name of registrant as specified in its	
Cayman Islands (State or other jurisdiction of incorporation or or	ganization)	98-1480821 (I.R.S. Employer Identification No.)
611 Gateway Blvd., Suite 223 South San Francisco, California (Address of principal executive offices)		94080 (Zip Code)
Securities to	be registered pursuant to Section 12	(b) of the Act:
Title of each class to be so registered		Name of exchange on which each class is to be registered
American depositary shares, each representing thr Shares, par value US\$0.0001 per share		The Nasdaq Stock Market LLC The Nasdaq Stock Market LLC*
shares represent the right to receive the ordinary share	es and are being registered under the	n the Nasdaq Stock Market LLC. The American depositary Securities Act of 1933 pursuant to a separate Registration stration under Section 12(a) of the Securities Exchange Ac
If this form relates to the registration of a class of securities $A.(c)$, check the following box. \boxtimes	es pursuant to Section 12(b) of the Exc	change Act and is effective pursuant to General Instruction
If this form relates to the registration of a class of securities $A.(d)$, check the following box. \square	es pursuant to Section 12(g) of the Exc	change Act and is effective pursuant to General Instruction
If this form relates to the registration of a class of securitie	s concurrently with a Regulation A of	ering, check the following box.
Securities Act regis	tration statement file number to whi 333-269200	ch this form relates:
Securities to	be registered pursuant to Section 12 None	(g) of the Act:

Item 1. Description of Registrant's Securities to be Registered.

The description of the securities of Structure Therapeutics Inc. (the "Registrant") being registered is set forth under "Description of Share Capital" and "Description of American Depositary Shares" in the Registrant's registration statement on Form S-1 (File No. 333-269200) (the Registration Statement"), initially filed with the Securities and Exchange Commission (the "Commission") on January 12, 2023, as amended, including any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with such Registration Statement, which description is incorporated herein by reference.

Item 2. Exhibits.

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Structure Therapeutics Inc.

Date: January 30, 2023 By: /s/ Raymond Steven

By: /s/ Raymond Stevens
Name: Raymond Stevens, Ph.D.
Title: Chief Executive Officer